Grant: CIHR Fellowship
University of Calgary
$135,000.00
Magnetic Resonance Imaging of a drug-enhanced trial of repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder
FY 2023-24
Summary
Almost 10% of Canadians will experience Major Depressive Disorder in their lifetime. This severe and recurrent mental illness significantly impacts both the individual and society, with the direct and indirect costs exceeding $30 billion annually. Up to 70% of patients with major depression do not fully recover, representing 1.5 million Canadians at any given time. For these patients, non-invasive neurostimulation such as repetitive Transcranial Magnetic Stimulation (rTMS) is an alternative treatment. rTMS delivered to the dorsolateral prefrontal cortex (DLFPC) is evidence-based and Health Canada approved, but it does not work for everyone, as up to 50% of patients do not benefit from rTMS.
Recently, our lab demonstrated that the positive treatment effects of rTMS can be enhanced by pairing it with the drug D-Cycloserine. My project will use Magnetic Resonance Imaging (MRI) to expand on this important finding, and determine how the combination of D-Cycloserine with rTMS results in greater improvements in a large, replication study.
My project will focus on a key brain region in depression, the Anterior Cingulate Cortex (ACC). The connection between ACC and DLPFC has been shown to be predictive of response to rTMS in patients with major depression. Further, successful rTMS has been shown to reduce levels of a specific neurotransmitter, GABA, within the ACC. Using MRI, I will measure the functional connection between the DLPFC and ACC and change in GABA in the ACC following rTMS with and without D-Cycloserine. This study will provide insight into the mechanisms of rTMS and rTMS+D-Cycloserine, enabling further improvements to treatment. Additionally, this study will characterize individuals who benefit from this intervention to improve treatment targeting for this debilitating disorder.
This information will be immensely valuable to improve treatment for major depression, particularly for patients for whom current medications are ineffective.
Department
Program
CIHR Fellowship
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
492472
Name
DeMayo Marilena M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Fellowships - Post-PhD
Projecttitle
Magnetic Resonance Imaging of a drug-enhanced trial of repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Functional Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Major Depressive Disorder; Repetitive Transcranial Magnetic Stimulation
Abstract
Almost 10% of Canadians will experience Major Depressive Disorder in their lifetime. This severe and recurrent mental illness significantly impacts both the individual and society, with the direct and indirect costs exceeding $30 billion annually. Up to 70% of patients with major depression do not fully recover, representing 1.5 million Canadians at any given time. For these patients, non-invasive neurostimulation such as repetitive Transcranial Magnetic Stimulation (rTMS) is an alternative treatment. rTMS delivered to the dorsolateral prefrontal cortex (DLFPC) is evidence-based and Health Canada approved, but it does not work for everyone, as up to 50% of patients do not benefit from rTMS.
Recently, our lab demonstrated that the positive treatment effects of rTMS can be enhanced by pairing it with the drug D-Cycloserine. My project will use Magnetic Resonance Imaging (MRI) to expand on this important finding, and determine how the combination of D-Cycloserine with rTMS results in greater improvements in a large, replication study.
My project will focus on a key brain region in depression, the Anterior Cingulate Cortex (ACC). The connection between ACC and DLPFC has been shown to be predictive of response to rTMS in patients with major depression. Further, successful rTMS has been shown to reduce levels of a specific neurotransmitter, GABA, within the ACC. Using MRI, I will measure the functional connection between the DLPFC and ACC and change in GABA in the ACC following rTMS with and without D-Cycloserine. This study will provide insight into the mechanisms of rTMS and rTMS+D-Cycloserine, enabling further improvements to treatment. Additionally, this study will characterize individuals who benefit from this intervention to improve treatment targeting for this debilitating disorder.
This information will be immensely valuable to improve treatment for major depression, particularly for patients for whom current medications are ineffective.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
DeMayo, Marilena M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~